To address conflicting reports about the cardiovascular safety of DPP-4 inhibitors, researchers performed a large retrospective cohort study.
Evaluate Cardiometabolic Risk in Youth
How well do waist-to-height ratios calculated using NHANES and WHO protocols indicate cardiometabolic risk in youth with diabetes?
Dapagliflozin: All-Cause & Cardiovascular Mortality
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Strength Training & Incident Diabetes, CVD Rates
Strength training can improve glycemic control among diabetics, but can it reduce rates of type 2 diabetes and cardiovascular disease?
Intentional Eating: CV Health & Obesity
The American Heart Association released a statement about the impact meal timing and frequency has on cardiometabolic health and obesity.
Sexual Dysfunction in Diabetes
Asking about and treating sexual dysfunction may not only improve a patient’s quality of life, but also address serious health problems down the road.
Diabetic Dyslipidemia: Fenofibrate plus Statin
Further study is needed, but adding fenofibrate to statins may decrease cardiovascular disease events in certain patients with type 2 diabetes.
Nut Consumption: Time for New Recommendations?
Past studies have linked nut consumption to decreased risk of CVD & all-cause mortality, but have not systematically evaluated less common causes of death.
Statin Therapy with Type 2 Diabetes & Nephropathy
In patients with type 2 diabetes complicated by nephropathy, what is the real life effect of statin therapy on cardiovascular disease prevention?
CV Risks and Diabetes: Puerto Rican Population
Dr. Bobby Lazzara discusses a study looking at certain demographics and cardiovascular complications in a diabetic patient population in Puerto Rico.
Metformin: Cardioprotective in Type 1 Diabetes?
Can metformin’s cardioprotective effect also benefit patients with type 1 diabetes? Dr. Bobby Lazzara discusses a small study of 23 patients.
Top 10: Endocrinology Network 2016
SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.
Interesting T2DM: Psychosocial Care & CV, DM Risk
Our December list includes new care guidelines from the ADA, a new indication for an SGLT2i, and effects of PCI on CV, DM risk.
AHA 2016: Obesity Paradox in Heart Failure
Does the obesity paradox exist in heart failure? What roles do ejection fraction and type 2 diabetes & acute decompensated heart failure play?
Bariatric Surgery: Effects on CV Health, Diabetes
Researchers investigated the impact of bariatric surgery on cardiovascular health & diabetes, as well as statin therapy & visceral adipose tissue.
By clicking Accept, you agree to become a member of the UBM Medica Community.